Clinical trial

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-03-01

PhasePHASE1

Study timeline

Study start (unknown)2015-03-01Date precision: month

Registry last updated2015-07-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Infection, Human Immunodeficiency Virusunresolved

Interventions

Cabotegravir 30 mg current formulationDRUG

Cabotegravir 30 mg micronized new formulation 500 MDRUG

Cabotegravir 30 mg unmicronized new formulation 500 UDRUG

Cabotegravir 30 mg micronized new formulation 650 MDRUG

Cabotegravir 30 mg unmicronized new formulation 650 UDRUG

Sponsors & collaborators

ViiV Healthcarelead sponsor

Mapped research locations

Overland ParkKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02345707 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.